You are here

Recent Pfizer Press Releases

2/21/17 8:00am EST
Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration

Application Requests Approval for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults

Pfizer Inc. (NYSE:PFE) today announced that a Biologics License Application (BLA) for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA). Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

more...
2/17/17 12:00pm EST
New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a

Pfizer in partnership with Celltrion Healthcare presents new data for INFLECTRA in Crohn’s disease

Data announced jointly today by Pfizer Inc.

more...
2/16/17 8:00am EST
Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab)

Pfizer Inc. (NYSE:PFE) announced today top-line results from ORAL Strategy, a Phase 3B/4 study of XELJANZ® (tofacitinib citrate) 5mg twice daily (BID) in the treatment of moderate to severe rheumatoid arthritis (RA). ORAL Strategy is the first trial to compare a JAK inhibitor as monotherapy or in combination with methotrexate (MTX) versus adalimumab (Humira) plus MTX in MTX inadequate responders using ACR50 at Month 6 as the primary endpoint. There were three comparisons,which found:

more...
2/9/17 8:30am EST
Relationship Expert Teams Up with Pfizer to Address Intimacy and Relationship Issues for People Living with Chronic Diseases

Logan Levkoff, Ph.D., addresses tough topics for those living with rheumatoid arthritis on Arthritis.com

Nationally-recognized relationship expert and author, Logan Levkoff, Ph.D., has partnered with Pfizer Inc. (NYSE:PFE) to fill a void in information available to people living with chronic diseases: relationship advice. Levkoff will address the topics of relationships and intimacy for those living with a chronic condition, like rheumatoid arthritis (RA), on the newly re-launched Arthritis.com site. The website is a place where people living with a chronic illness can find inspiration, lifestyle advice, tools, and disease information.

more...
1/31/17 6:45am EST
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2016 RESULTS

PROVIDES 2017 FINANCIAL GUIDANCE

Please find Pfizer’s press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink: http://www.pfizer.com/system/files/presentation/Q4_2016_PFE_Earnings_Pre...

more...
1/27/17 7:00am EST
Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ® (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis

Pfizer Inc. (NYSE:PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) for the treatment of patients with moderate to severe active rheumatoid arthritis (RA). The CHMP’s opinion will now be sent to the European Commission (EC) for final decision.

more...
1/26/17 8:00am EST
Pfizer Announces Positive Top-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection

Pfizer’s C. difficile Vaccine Candidate to Commence Phase 3 Study in First Half of 2017

C. difficile is an Increasing Worldwide Concern Associated with Approximately 29,000 Annual Deaths in the U.S. Alone

Pfizer Inc. (NYSE:PFE) announced today that the Phase 2 study evaluating the Company’s Clostridium difficile (C. difficile) vaccine candidate, PF-06425090, provided positive data, based on a pre-planned interim analysis. The randomized Phase 2 study (NCT02561195) examined the safety, tolerability, and immunogenicity of the vaccine in healthy adults 65 to 85 years of age. Pfizer’s vaccine candidate is designed to help prevent C.

more...
1/5/17 8:30am EST
Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab)

Marks Pfizer’s third proposed biosimilar pipeline molecule2 to report positive top-line data results within the past four months

Pfizer Inc. (NYSE:PFE) today announced that the comparative, confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 (ACR20) response rate at Week 12. This trial is evaluating the efficacy, safety, and immunogenicity of PF-06410293 compared to Humira® (adalimumab), each taken in combination with methotrexate, in patients with moderate to severe rheumatoid arthritis. PF-06410293 is being developed as a potential biosimilar to Humira.

more...
1/3/17 11:00am EST
Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts

Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2016 Performance Report, to be issued that morning.

more...
1/3/17 10:00am EST
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Pfizer Innovative Health, Frank D’Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, and Mikael Dolsten, President, Worldwide Research and Development, and at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017 at 10:30 a.m. Pacific Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “35th Annual J.P.

more...